|
1
|
GBD 2013 Risk Factors Collaborators, ;
Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S,
Brauer M, Burnett R, Casey D, Coates MM, et al: Global, regional,
and national comparative risk assessment of 79 behavioural,
environmental and occupational, and metabolic risk factors or
clusters of risks in 188 countries, 1990–2013: A systematic
analysis for the Global Burden of Disease Study 2013. Lancet.
386:2287–2323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kearney PM, Whelton M, Reynolds K, Muntner
P, Whelton PK and He J: Global burden of hypertension: Analysis of
worldwide data. Lancet. 365:217–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lafeber M, Spiering W, Visseren FL and
Grobbee DE: Multifactorial prevention of cardiovascular disease in
patients with hypertension: The cardiovascular polypill. Curr
Hypertens Rep. 18:402016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park C, Wang G, Durthaler JM and Fang J:
Cost-effectiveness analyses of antihypertensive medicines: A
systematic review. Am J Prev Med. 53:S131–S142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garjón J, Saiz LC, Azparren A, Elizondo
JJ, Gaminde I, Ariz MJ and Erviti J and Erviti J: First-line
combination therapy versus first-line monotherapy for primary
hypertension. Cochrane Database Syst Rev. 1:CD0103162017.PubMed/NCBI
|
|
6
|
Oparil S, Acelajado MC, Bakris GL,
Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter
NR, Rodgers A, et al: Hypertension. Nat Rev Dis Primers.
4:180142018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho J, Kim C, Kang DR and Park JB:
Hyperuricemia and uncontrolled hypertension in treated hypertensive
patients: K-MetS Study. Medicine (Baltimore). 95:e41772016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chow CK, Teo KK, Rangarajan S, Islam S,
Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, et al
PURE (Prospective Urban Rural Epidemiology) Study investigators, :
Prevalence, awareness, treatment, and control of hypertension in
rural and urban communities in high-, middle-, and low-income
countries. JAMA. 310:959–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fryar CD, Ostchega Y, Hales CM, Zhang G
and Kruszon-Moran D: Hypertension prevalence and control among
adults: United States, 2015–2016. NCHS Data Brief. 289:1–8.
2017.
|
|
10
|
National Institutes of Health (NIH), .
National Center for Complementary and Integrative Health (NCCIH):
Complementary, Alternative, or Integrative Health: What's In a
Name? https://nccih.nih.gov/health/integrative-health
|
|
11
|
Afolayan AJ and Wintola OA: Dietary
supplements in the management of hypertension and diabetes - a
review. Afr J Tradit Complement Altern Med. 11:248–258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Upadrasta A and Madempudi RS: Probiotics
and blood pressure: Current insights. Integr Blood Press Control.
9:33–42. 2016.PubMed/NCBI
|
|
13
|
Santos-Ocaña C, Do TQ, Padilla S, Navas P
and Clarke CF: Uptake of exogenous coenzyme Q and transport to
mitochondria is required for bc1 complex stability in yeast coq
mutants. J Biol Chem. 277:10973–10981. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamagami T, Shibata N and Folkers K:
Bioenergetics in clinical medicine. Studies on coenzyme Q10 and
essential hypertension. Res Commun Chem Pathol Pharmacol.
11:273–288. 1975.PubMed/NCBI
|
|
15
|
Langsjoen PH and Langsjoen AM: Overview of
the use of CoQ10 in cardiovascular disease. Biofactors. 9:273–284.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Digiesi V, Cantini F, Oradei A, Bisi G,
Guarino GC, Brocchi A, Bellandi F, Mancini M and Littarru GP:
Coenzyme Q10 in essential hypertension. Mol Aspects Med. 15 (Suppl
1):s257–s263. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh RB, Niaz MA, Rastogi SS, Shukla PK
and Thakur AS: Effect of hydrosoluble coenzyme Q10 on blood
pressures and insulin resistance in hypertensive patients with
coronary artery disease. J Hum Hypertens. 13:203–208. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pepe S, Marasco SF, Haas SJ, Sheeran FL,
Krum H and Rosenfeldt FL: Coenzyme Q10 in cardiovascular disease.
Mitochondrion. 7 (Suppl):S154–S167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng
K, Leong JY and Watts GF: Coenzyme Q10 in the treatment of
hypertension: A meta-analysis of the clinical trials. J Hum
Hypertens. 21:297–306. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Serebruany VL, Ordonez JV, Herzog WR,
Rohde M, Mortensen SA, Folkers K and Gurbel PA: Dietary coenzyme
Q10 supplementation alters platelet size and inhibits human
vitronectin (CD51/CD61) receptor expression. J Cardiovasc
Pharmacol. 29:16–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duffy SJ, Gokce N, Holbrook M, Huang A,
Frei B, Keaney JF Jr and Vita JA: Treatment of hypertension with
ascorbic acid. Lancet. 354:2048–2049. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Afrose SA, Fahmeed A, Mujtaba A, Khan M
and Noorulla SM: A study on effects of combining vitamin C with
hypertension therapy. Int J Pharm Res Allied Sci. 4:142–146.
2015.
|
|
23
|
Juraschek SP, Guallar E, Appel LJ and
Miller ER III: Effects of vitamin C supplementation on blood
pressure: A meta-analysis of randomized controlled trials. Am J
Clin Nutr. 95:1079–1088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ried K, Travica N and Sali A: The acute
effect of high-dose intravenous vitamin C and other nutrients on
blood pressure: A cohort study. Blood Press Monit. 21:160–167.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahajan AS, Babbar R, Kansal N, Agarwal SK
and Ray PC: Antihypertensive and antioxidant action of amlodipine
and vitamin C in patients of essential hypertension. J Clin Biochem
Nutr. 40:141–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Padayatty SJ, Sun AY, Chen Q, Espey MG,
Drisko J and Levine M: Vitamin C: Intravenous use by complementary
and alternative medicine practitioners and adverse effects. PLoS
One. 5:e114142010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Connor SL and Connor WE: Are fish oils
beneficial in the prevention and treatment of coronary artery
disease? Am J Clin Nutr. 66 (Suppl 4):1020S–1031S. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simopoulos AP: Omega-3 fatty acids in
health and disease and in growth and development. Am J Clin Nutr.
54:438–463. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prisco D, Paniccia R, Bandinelli B,
Filippini M, Francalanci I, Giusti B, Giurlani L, Gensini GF,
Abbate R and Neri Serneri GG: Effect of medium-term supplementation
with a moderate dose of n-3 polyunsaturated fatty acids on blood
pressure in mild hypertensive patients. Thromb Res. 91:105–112.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bønaa KH, Bjerve KS, Straume B, Gram IT
and Thelle D: Effect of eicosapentaenoic and docosahexaenoic acids
on blood pressure in hypertension. A population-based intervention
trial from the Tromsø study. N Engl J Med. 322:795–801. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rasmussen BM, Vessby B, Uusitupa M,
Berglund L, Pedersen E, Riccardi G, Rivellese AA, Tapsell L and
Hermansen K; KANWU Study Group, : Effects of dietary saturated,
monounsaturated, and n-3 fatty acids on blood pressure in healthy
subjects. Am J Clin Nutr. 83:221–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morris MC, Sacks F and Rosner B: Does fish
oil lower blood pressure? A meta-analysis of controlled trials.
Circulation. 88:523–533. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yagi S, Fukuda D, Aihara KI, Akaike M,
Shimabukuro M and Sata M: n-3 Polyunsaturated fatty acids:
Promising nutrients for preventing cardiovascular disease. J
Atheroscler Thromb. 24:999–1010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Innes JK and Calder PC: The differential
effects of eicosapentaenoic acid and docosahexaenoic acid on
cardiometabolic risk factors: A systematic review. Int J Mol Sci.
19:E5322018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jovanovski E, Bateman EA, Bhardwaj J,
Fairgrieve C, Mucalo I, Jenkins AL and Vuksan V: Effect of
Rg3-enriched Korean red ginseng (Panax ginseng) on arterial
stiffness and blood pressure in healthy individuals: A randomized
controlled trial. J Am Soc Hypertens. 8:537–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mucalo I, Jovanovski E, Rahelić D, Božikov
V, Romić Z and Vuksan V: Effect of American ginseng (Panax
quinquefolius L.) on arterial stiffness in subjects with type-2
diabetes and concomitant hypertension. J Ethnopharmacol.
150:148–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim JH: Cardiovascular diseases and
Panax ginseng: A review on molecular mechanisms and medical
applications. J Ginseng Res. 36:16–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen H, Yin J, Deng Y, Yang M, Xu L, Teng
F, Li D, Cheng Y, Liu S, Wang D, et al: The protective effects of
ginsenoside Rg1 against hypertension target-organ damage in
spontaneously hypertensive rats. BMC Complement Altern Med.
12:532012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee NH and Son CG: Systematic review of
randomized controlled trials evaluating the efficacy and safety of
ginseng. J Acupunct Meridian Stud. 4:85–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stavro PM, Woo M, Heim TF, Leiter LA and
Vuksan V: North American ginseng exerts a neutral effect on blood
pressure in individuals with hypertension. Hypertension.
46:406–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim YS, Woo JY, Han CK and Chang IM:
Safety analysis of Panax ginseng in randomized clinical
trials: A systematic review. Medicines (Basel). 2:106–126. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reinhart KM, Coleman CI, Teevan C,
Vachhani P and White CM: Effects of garlic on blood pressure in
patients with and without systolic hypertension: A meta-analysis.
Ann Pharmacother. 42:1766–1771. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ried K, Frank OR, Stocks NP, Fakler P and
Sullivan T: Effect of garlic on blood pressure: A systematic review
and meta-analysis. BMC Cardiovasc Disord. 8:132008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang HP, Yang J, Qin LQ and Yang XJ:
Effect of garlic on blood pressure: A meta-analysis. J Clin
Hypertens (Greenwich). 17:223–231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ried K: Garlic lowers blood pressure in
hypertensive individuals, regulates serum cholesterol, and
stimulates immunity: An updated meta-analysis and review. J Nutr.
146:389S–396S. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sobenin IA, Andrianova IV, Fomchenkov IV,
Gorchakova TV and Orekhov AN: Time-released garlic powder tablets
lower systolic and diastolic blood pressure in men with mild and
moderate arterial hypertension. Hypertens Res. 32:433–437. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nakasone Y, Nakamura Y, Yamamoto T and
Yamaguchi H: Effect of a traditional Japanese garlic preparation on
blood pressure in prehypertensive and mildly hypertensive adults.
Exp Ther Med. 5:399–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
United States Pharmacopeial Convention I.
United States Pharmacopoeia 38 Garlic Fluid Extract USP 28-NF 33.
United States Pharmacopeial Convention; Rockville, MD: pp.
6052–6055. 2015
|
|
49
|
Ried K, Frank OR and Stocks NP: Aged
garlic extract reduces blood pressure in hypertensives: A
dose-response trial. Eur J Clin Nutr. 67:64–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ried K, Travica N and Sali A: The effect
of aged garlic extract on blood pressure and other cardiovascular
risk factors in uncontrolled hypertensives: The AGE at heart trial.
Integr Blood Press Control. 9:9–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ried K, Travica N and Sali A: The effect
of Kyolic aged garlic extract on gut microbiota, inflammation, and
cardiovascular markers in hypertensives: The GarGIC trial. Front
Nutr. 5:1222018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ushijima M, Takashima M, Kunimura K,
Kodera Y, Morihara N and Tamura K: Effects of S-1-propenylcysteine,
a sulfur compound in aged garlic extract, on blood pressure and
peripheral circulation in spontaneously hypertensive rats. J Pharm
Pharmacol. 70:559–565. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Morihara N, Sumioka I, Moriguchi T, Uda N
and Kyo E: Aged garlic extract enhances production of nitric oxide.
Life Sci. 71:509–517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takashima M, Kanamori Y, Kodera Y,
Morihara N and Tamura K: Aged garlic extract exerts
endothelium-dependent vasorelaxant effect on rat aorta by
increasing nitric oxide production. Phytomedicine. 24:56–61. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Benavides GA, Squadrito GL, Mills RW,
Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE and
Kraus DW: Hydrogen sulfide mediates the vasoactivity of garlic.
Proc Natl Acad Sci USA. 104:17977–17982. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mohamadi A, Jarrell ST, Shi SJ, Andrawis
NS, Myers A, Clouatre D and Preuss HG: Effects of wild versus
cultivated garlic on blood pressure and other parameters in
hypertensive rats. Heart Dis. 2:3–9. 2000.PubMed/NCBI
|
|
57
|
Cruz C, Correa-Rotter R, Sánchez-González
DJ, Hernández-Pando R, Maldonado PD, Martínez-Martínez CM,
Medina-Campos ON, Tapia E, Aguilar D, Chirino YI, et al:
Renoprotective and antihypertensive effects of S-allylcysteine in
5/6 nephrectomized rats. Am J Physiol Renal Physiol.
293:F1691–F1698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Matsutomo T, Ushijima M, Kunimura K and
Ohtani M: Metabolomic study reveals the acute hypotensive effect of
S-1-propenylcysteine accompanied by alteration of the plasma
histidine level in spontaneously hypertensive rats. J Pharm Biomed
Anal. 168:148–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Matsutomo T, Ushijima M, Kodera Y,
Nakamoto M, Takashima M, Morihara N and Tamura K: Metabolomic study
on the antihypertensive effect of S-1-propenylcysteine in
spontaneously hypertensive rats using liquid chromatography coupled
with quadrupole-Orbitrap mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci. 1046:147–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ackermann RT, Mulrow CD, Ramirez G,
Gardner CD, Morbidoni L and Lawrence VA: Garlic shows promise for
improving some cardiovascular risk factors. Arch Intern Med.
161:813–824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Borrelli F, Capasso R and Izzo AA: Garlic
(Allium sativum L.): Adverse effects and drug interactions
in humans. Mol Nutr Food Res. 51:1386–1397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Varshney R and Budoff MJ: Garlic and Heart
Disease. J Nutr. 146:416S–421S. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Qi Y, Kim S, Richards EM, Raizada MK and
Pepine CJ: Gut microbiota: Potential for a unifying hypothesis for
prevention and treatment of hypertension. Circ Res. 120:1724–1726.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang T, Santisteban MM, Rodriguez V, Li E,
Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, et al:
Gut dysbiosis is linked to hypertension. Hypertension.
65:1331–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian
G, Wu S, Liu W, Cui Q, Geng B, et al: Gut microbiota dysbiosis
contributes to the development of hypertension. Microbiome.
5:142017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Naruszewicz M, Johansson ML,
Zapolska-Downar D and Bukowska H: Effect of Lactobacillus
plantarum 299v on cardiovascular disease risk factors in
smokers. Microbiome. 5:142017.PubMed/NCBI
|
|
67
|
Mizushima S, Ohshige K, Watanabe J, Kimura
M, Kadowaki T, Nakamura Y, Tochikubo O and Ueshima H: Randomized
controlled trial of sour milk on blood pressure in borderline
hypertensive men. Am J Hypertens. 17:701–706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Inoue K, Shirai T, Ochiai H, Kasao M,
Hayakawa K, Kimura M and Sansawa H: Blood-pressure-lowering effect
of a novel fermented milk containing gamma-aminobutyric acid (GABA)
in mild hypertensives. Eur J Clin Nutr. 57:490–495. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Aoyagi Y, Park S, Matsubara S, Honda Y,
Amamoto R, Kushiro A, Miyazaki K and Shephard RJ: Habitual intake
of fermented milk products containing Lactobacillus casei
strain Shirota and a reduced risk of hypertension in older people.
Benef Microbes. 8:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Agerholm-Larsen L, Raben A, Haulrik N,
Hansen AS, Manders M and Astrup A: Effect of 8 week intake of
probiotic milk products on risk factors for cardiovascular
diseases. Eur J Clin Nutr. 54:288–297. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tabuchi M, Ozaki M, Tamura A, Yamada N,
Ishida T, Hosoda M and Hosono A: Antidiabetic effect of
Lactobacillus GG in streptozotocin-induced diabetic rats.
Biosci Biotechnol Biochem. 67:1421–1424. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Seppo L, Jauhiainen T, Poussa T and
Korpela R: A fermented milk high in bioactive peptides has a blood
pressure-lowering effect in hypertensive subjects. Am J Clin Nutr.
77:326–330. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Khalesi S, Sun J, Buys N and Jayasinghe R:
Effect of probiotics on blood pressure: A systematic review and
meta-analysis of randomized, controlled trials. Hypertension.
64:897–903. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tanida M, Yamano T, Maeda K, Okumura N,
Fukushima Y and Nagai K: Effects of intraduodenal injection of
Lactobacillus johnsonii La1 on renal sympathetic nerve
activity and blood pressure in urethane-anesthetized rats. Neurosci
Lett. 389:109–114. 2005. View Article : Google Scholar : PubMed/NCBI
|
